Disease Management and Medication Compliance

Abstract

Lack of medication compliance is harmful to health care systems from both a clinical and economic perspective. This study examines the methods that disease management organizations employ to identify nonadherent patients and to measure effectiveness of compliance programs for patients with diabetes, hyperlipidemia, and cystic fibrosis. In addition, this study investigates the degree to which disease managers assume risk in their contracts, and whether compliance strategies are being coordinated with payers' use of value-based insurance design, in which patient cost sharing is a function of the relative value of pharmaceuticals. This study's findings suggest that disease management may be falling short in terms of: (a) comprehensive commitment to expert-recommended at-home devices used to self-diagnose and measure health indicators; (b) early adoption of expert-recommended new technologies to measure and improve compliance; (c) intensity of use of standard tests in outpatient clinics; (d) coordination of compliance strategies with payers' use of value-based insurance design; and (e) the proportion of risk assumed in disease management contracts.

Association of Medicare Part D Medication Out‐of‐Pocket Costs with Utilization of Statin Medications

“…Insights from the value-based insurance design programs suggest that closing the gap could improve adherence rates and decrease adverse outcomes (Chernew et al 2010;Gibson et al 2010Gibson et al , 2011Kim et al 2011;Cohen, Christianson, and Feldman 2012). The 2012 Affordable Care Act provisions provide more support during the coverage gap, but beneficiaries still pay a portion of the manufacturer prices for drugs purchased in this period (50 percent for brand-name drugs and 86 percent for generic drugs).…”

Sharing health data in Belgium: A home care case study using the Vitalink platform

“…Examples are improper timing, inappropriate dosage and not being persistent. This can be due to disease, patient specific issues or financial constraints [38]. Theofilou [39] states that compliance to prescribed medication is a complex phenomenon, which depends on an interaction of different factors, e.g., personal influences and economic factors.…”

Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network

“…Our proposal optimizes CER to individual care and treatment innovation to advance our knowledge about the effectiveness of various clinical strategies [51]. Additionally, adherence to person medication compliance should improve further reducing cost and improving clinical outcomes [52]. …”